2021 Fiscal Year Final Research Report
Relation of HLA types and adverse effects of the immune check inhibitor in lung cancer patients
| Project/Area Number |
18K08806
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 55040:Respiratory surgery-related
|
|---|
| Research Institution | University of Occupational and Environmental Health, Japan |
|---|
Principal Investigator |
Taira Akihiro 産業医科大学, 医学部, 助教 (00813263)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
市来 嘉伸 産業医科大学, 医学部, 非常勤医師 (80419837)
米田 和恵 産業医科大学, 医学部, 講師 (80724806)
田中 文啓 産業医科大学, 医学部, 教授 (10283673)
|
|---|
| Project Period (FY) |
2018-04-01 – 2022-03-31
|
| Keywords | 肺癌 / 免疫チェックポイント阻害薬 / 免疫関連有害事象 |
|---|
| Outline of Final Research Achievements |
Primary lung cancer is the leading cause of death from malignant neoplasms in Japan and has a poor prognosis. Immune-related adverse event (irAE) occur at a certain rate with immune checkpoint inhibitors. The aim of this study was to investigate the association of HLA subtypes with the incidence and efficacy of immune-related adverse events in immune checkpoint inhibitors.It was suggested that HLA A26 positivity may predominantly increase the incidence of adverse events and adrenal insufficiency, while the incidence of adverse events may be lower in HLA DR4 positivity.
|
| Free Research Field |
呼吸器外科
|
| Academic Significance and Societal Importance of the Research Achievements |
原発性肺癌は日本人の悪性新生物の死因第1位を占める予後の悪い疾患である。免疫チェックポイント阻害薬の登場により、肺がん薬物療法の予後は飛躍的に延長した。ある一定の確立で免疫関連の有害事象が発症することが分かっている。どのようなタイプの人に起こりやすいかといった因子は明確になっていない。本研究はそれを明らかにすることで、有害事象の早期発見や治療介入が期待される。
|
